newsfilter
← Latest News
Business Wire·

AVEO Oncology Reports First Quarter 2021 Financial Results and Provides Business Update

– U.S. Commercial Launch Underway with Fully Deployed Sales Force Following FDA Approval of FOTIVDA® (tivozanib) on March 10, 2021 – – FOTIVDA Net Product Revenue of $1.1 Million from Initial Distributor Orders in the Last Week of Q1; All Dist